Navigation Links
CE Mark Granted for Wound Spray Based on Sangui Patent
Date:4/6/2012

WITTEN, Germany, April 6, 2012 /PRNewswire/ --

Sales Start Under Granulox Brand Name Imminent

Based on a patent by Sangui, the technology for a spray aiming at improved healing of chronic wounds is now available. According to a notification by SastoMed GmbH a certification as class III medical product was granted. Global licensee SastoMed will be in charge of marketing and distribution. The CE mark according to sections 6 and 7 of the Medical Devices Act authorizes production, distribution and sales of the product in all member countries of the European Union. SastoMed have also informed Sangui BioTech GmbH that the market entry of the product is imminent.

SastoMed Managing Director Michael Sander said: "This is a definitive breakthrough enabling us to capitalize on the great opportunities this unique product offers. We now sell the only therapeutic which can help to soothe the problem of hypoxia i.e. the lack of oxygen supply to chronic wounds. This technology can be regarded as a significant innovation in wound treatment. Already, we experience numerous individual requests and a growing awareness among leading wound management experts. We are excited to offer them a highly effective supplement to the existing treatments."

The CE mark certification for Granulox was obtained only 16 months after the founding of the joint venture company SastoMed by Sangui BioTech GmbH and SanderStrothman GmbH and well ahead of the initial two year road map. Numerous additional inquiries were required to prepare the demanding documentation for the certification as class III medical product, cornerstone of the process of converting the patent into a production process, impeccable both from an economic and authorization point of view. In addition, preparatory works included the developing of completely new manufacturing processes yielding considerable efficiency improvements.

"With the imminent market entry of the product our company enters a new stage", Hubertus Schmelz, Managing Director of SanguiBioTech GmbH emphasized. "It also confirms that the cooperation with SanderStrothmann was and continues to be a decisive step ahead for us with both sides now benefiting from the professionalism and the good mutual relationship established over the past years."

Details of the sales plan as well as of future activities are to be disclosed in due course.

Sangui BioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc. (http://www.otcmarkets.com: SGBI)

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions.  Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information please contact:
Joachim Fleing
Phone: +49(160)741-27-17
Fax: +49(2302)915-191
email: fleing@sangui.de


'/>"/>
SOURCE Sangui BioTech International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7)
2. NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents
3. BioDrain Medical, Inc. Granted Canadian Patent for its Streamway® Surgical Fluid Management System
4. Cephalon Granted Temporary Restraining Order in AMRIX® Patent Litigation
5. Ganeden Biotech Granted 100th Probiotic Patent
6. Biomerix Granted US Patent for Its Proprietary Biomaterial Platform Technology
7. EmergingMed Granted Patent
8. Spectral granted IDE approval by U.S. FDA to conduct pivotal trial for Toraymyxin(TM)
9. Appeal of Lawsuit by Former Officer Dismissed; Request for Sanctions Granted
10. YM BioSciences granted two US patents for AeroLEF(R)
11. Viron granted U.S. Patents for Organ Transplant and Arthritis Drug Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Diego, CA (PRWEB) , ... June 27, 2016 , ... ... solutions for clinical trials, announced today the Clinical Reach Virtual Patient Encounter ... their care circle with the physician and clinical trial team. , Using the CONSULT ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. ... the faculty of the University of North Carolina Kenan-Flagler Business School ... entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading ...
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks , ... industrial engineering, was today awarded as one of ... of the world,s most innovative companies. Ginkgo Bioworks ... for the real world in the nutrition, health ... work directly with customers including Fortune 500 companies ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
Breaking Biology Technology:
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
Breaking Biology News(10 mins):